Clinical Trial Update: Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating the efficacy and safety of the monoclonal antibody Clesrovimab (MK-1654) for respiratory syncytial virus infection i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Clesrovimab (clesrovimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Respiratory Syncytial Virus Infection | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-02-04